Polycystic kidney disease (PKD) Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Polycystic kidney disease (PKD) Pipeline Analysis report covers 15 drugs currently in different phases of development. Polycystic kidney disease is an inherited kidney disorder characterised by formation of fluid filled cysts within the kidneys impairing kidney function and eventually leading to kidney failure. Symptoms include pain or tenderness in the abdomen, frequent urination, blood in urine, pain or heaviness in the back, pale skin color, fatigue and joint pain. The disease is diagnosed by imaging tests such as abdominal ultrasound, abdominal MRI scan and intravenous pyelogram
The report provides Polycystic kidney disease treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment. Diagnosis of the disease is done through Skin biopsy for immunofluorescent mapping, Genetic testing and prenatal testing.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report include Angion Biomedica Corp., Conatus Pharmaceuticals Inc., and NovaTarg Therapeutics among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration